Abstract:Albendazole (a benzimidazole) and ivermectin (a macrocyclic lactone) are the two most commonly co-administered anthelmintic drugs in mass-drug administration programs worldwide. Despite emerging resistance, we do not fully understand the mechanisms of resistance to these drugs nor the consequences of delivering them in combination. Albendazole resistance has primarily been attributed to variation in the drug target, a beta-tubulin gene. Ivermectin targets glutamate-gated chloride channels (GluCls), but it is unknown whether GluCl genes are involved in ivermectin resistance in nature. Using Caenorhabditis elegans , we defined the fitness costs associated with loss of the drug target genes singly or in combinations of the genes that encode GluCl subunits. We quantified the loss-of-function effects on three traits: (i) multi-generational competitive fitness, (ii) fecundity, and (iii) development. In competitive fitness and development assays, we found that a deletion of the beta-tubulin gene ben-1 conferred albendazole resistance, but ivermectin resistance required the loss of two GluCl genes ( avr-14 and avr-15 ). The fecundity assays revealed that loss of ben-1 did not provide any fitness benefit in albendazole conditions and that no GluCl deletion mutants were resistant to ivermectin. Next, we searched for evidence of multi-drug resistance across the three traits. Loss of ben-1 did not confer resistance to ivermectin, nor did loss of any single GluCl subunit or combination confer resistance to albendazole. Finally, we assessed the development of 124 C . elegans wild strains across six benzimidazoles and seven macrocyclic lactones to identify evidence of multi-drug resistance between the two drug classes and found a strong phenotypic correlation within a drug class but not across drug classes. Because each gene affects various aspects of nematode physiology, these results suggest that it is necessary to assess multiple fitness traits to evaluate how each gene contributes to anthelmintic resistance. Control of parasitic nematodes often depends on mass-drug administration (MDA) programs, where combinations of anthelmintics are distributed to at-risk populations. Two commonly co-administered anthelmintic drugs in MDA programs are albendazole and ivermectin, and resistance to both drugs has emerged. Although the mechanism of resistance (MoR) to albendazole has been primarily attributed to variation in a beta-tubulin gene, the MoR to ivermectin remains unknown. Ivermectin acts through pentameric glutamate-gated chloride channels (GluCls). However, it is unclear whether genes that encode GluCls are involved in ivermectin resistance in parasitic nematodes. Using Caenorhabditis elegans , we quantified the fitness costs associated with deletions of the beta-tubulin gene ben-1 and three genes encoding GluCl subunits avr-14 , avr-15 , and glc-1 on three traits: (i) multi-generational competitive fitness, (ii) fecundity, and (iii) development. We found different anthelmintic responses across strains and traits but no evidence of multi-drug resistance. Our results suggest that multiple traits should be considered to understand resistance comprehensively and that the determination of whether a gene plays a role in anthelmintic resistance depends on the trait measured. Understanding the quantitative effects and fitness-associated costs of each GluCl subunit in C . elegans can help explain the costs of mutations in these subunits in parasites.

Worldwide absence of canonical benzimidazole resistance-associated mutations within β-tubulin genes from Ascaris

An Inactivated Bacterium (paraprobiotic) Expressing Bacillus Thuringiensis Cry5B As a Therapeutic for Ascaris and Parascaris Spp. Infections in Large Animals.

An Extensive Comparison of the Effect of Anthelmintic Classes on Diverse Nematodes

Quantitative tests of albendazole resistance in beta-tubulin mutants

The New Anthelmintic Tribendimidine is an L-type (levamisole and Pyrantel) Nicotinic Acetylcholine Receptor Agonist

Quantitative lipidomic analysis of Ascaris suum.

Bacillus Thuringiensis-Derived Cry5B Has Potent Anthelmintic Activity Against Ascaris Suum.

In Vivo and in Vitro Studies of Cry5B and Nicotinic Acetylcholine Receptor Agonist Anthelmintics Reveal a Powerful and Unique Combination Therapy Against Intestinal Nematode Parasites

Recombinant Paraprobiotics As a New Paradigm for Treating Gastrointestinal Nematode Parasites of Humans.

Nitazoxanide: nematicidal mode of action and drug combination studies.

Discovery of a Highly Synergistic Anthelmintic Combination That Shows Mutual Hypersusceptibility

A 4 year observation of gastrointestinal nematode egg counts, nemabiomes and the benzimidazole resistance genotypes of Teladorsagia circumcincta on a Scottish sheep farm

The assessment of single nucleotide polymorphisms in the ß-tubulin genes in human soil-transmitted helminths exposed to different pressure with benzimidazole drugs

Genomics of the Parasitic Nematode Ascaris and Its Relatives

Quantifying the fitness effects of resistance alleles with and without anthelmintic selection pressure using

Naturally occurring variation in a cytochrome P450 modifies thiabendazole responses independent of beta-tubulin

Quantifying the fitness effects of resistance alleles with and without anthelmintic selection pressure using Caenorhabditis elegans

Ascaris Suum Draft Genome

Extensive Hybridization Between Pig and Human Ascaris Identifies a Highly Interbred Species Complex Infecting Humans

Effectiveness of benzimidazole treatments against Haemonchus contortus in sheep and goats - do they produce similar responses?

Molecular evidence of hybridization between pig and human <i>Ascaris</i> indicates an interbred species complex infecting humans